Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT07133113Recruiting
Effects of treatments in autoimmune encephalitis
This study follows patients with autoimmune encephalitis (brain inflammation caused by the immune system) to see how treatments affect them in the medium term. It may help doctors learn which treatments work best for people with this condition.
BronAges Any age - NCT07135219Enrolling by invitationEarly Phase 1
Study of cizutamig for IgA nephropathy
This trial tests a new drug called cizutamig for people with IgA nephropathy who still have high protein in their urine despite trying other treatments. It aims to see if the drug can help protect kidney function.
BeijingAges 18–75 - NCT07131644RecruitingPhase 2
Stopping Sirolimus in KHE: A Careful Plan
This study looks at different ways to stop taking sirolimus for children with KHE, a rare blood vessel tumor. It helps find the best plan to prevent the tumor from coming back after treatment.
Chengdu, SichuanAges Any age - NCT07126678Recruiting
Zanubrutinib, Bendamustine, and Obinutuzumab for advanced follicular lymphoma
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT07134686Recruiting
Combined lung and ear-nose-throat care for asthma and sinusitis
This trial tests if seeing a lung specialist and an ear-nose-throat doctor together in one visit helps people with asthma and chronic sinusitis (with nasal polyps) feel better than seeing each specialist separately. You may qualify if your asthma or sinusitis is not well-controlled and you've used steroid pills in the past year.
MarseilleAges 18 years+ - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Seville, AndalusiaAges 18 years+ - NCT07126028Enrolling by invitation
Quality of life in kids after MIS-C
This study looks at how children feel and live their daily lives after recovering from MIS-C (a severe inflammatory condition linked to COVID-19). It compares them to healthy children of the same age and gender to see if there are any lasting effects.
Rijeka, Primorje-Gorski Kotar CountyAges 1 month–18 years - NCT06964581Recruiting
At-home cognitive training for multiple sclerosis
This study tests a at-home thinking and memory training program for people with multiple sclerosis. It aims to help improve mental skills like memory, attention, and planning through remote sessions.
Verona, veronaAges 18–65 - NCT07121777Recruiting
CAR T cell therapy for autoimmune diseases
This study tests a new type of cell therapy (CAR T cells) that targets certain immune cells to treat autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, and systemic sclerosis. It may help people whose disease is not well controlled with standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07118254RecruitingPhase 2
Eye drops for dry eye from graft-versus-host disease
This study tests whether a new eye drop (rhPRG4) can safely reduce dry eye symptoms caused by graft-versus-host disease (GVHD). It compares the active drops to an inactive placebo to see if they provide better relief.
Sydney, New South WalesAges 18–75 - NCT07118241RecruitingPhase 2
Testing a new eye drop for Sjögren's dry eye
This trial tests a new eye drop made from a natural protein (rhPRG4) to see if it safely and effectively relieves dry eye symptoms in people with Sjögren's syndrome. You'll be randomly assigned to receive the study drop or a placebo (inactive) drop for several weeks.
Sydney, New South WalesAges 18–80 - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07117669RecruitingPhase 1/Phase 2
Testing a new peanut allergy treatment (ENP-501)
This trial tests a new peanut allergy treatment called ENP-501. It aims to see if the medicine can safely help people with peanut allergy become less sensitive to peanuts.
Aurora, ColoradoAges 14–50 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07125872RecruitingPhase 2
New drug for relapsed B-cell lymphoma
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
JohannesburgAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT07116031RecruitingPhase 2
Belumosudil for children with chronic GVHD
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
Los Angeles, CaliforniaAges 1–18 - NCT07124936RecruitingPhase 1/Phase 2
Study of new drug plus standard care for large B-cell lymphoma
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT07123038Recruiting
Long-term safety study for gene-modified Treg therapy recipients
This study follows people who previously received a gene-modified Treg (regulatory T cell) therapy from Sonoma Biotherapeutics. It checks for long-term safety and does not involve any new treatment.
San Francisco, CaliforniaAges 18–71 - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.